PolTREG S.A. is an innovative startup aiming to develop therapies for autoimmune diseases. Established in 2015 as a spin-off from the Medical University of Gdańsk, the company focuses on commercializing patented TREG method, making it a global pioneer in cellular therapies based on TREGS cells. With an emphasis on breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS), PolTREG has shown promising results in safety and efficacy through completed phase I/II clinical trials in T1D and phase I in MS. The company is now ready for the next phase of trials and has undergone the EMA Scientific Advice procedure, demonstrating its commitment to regulatory compliance and scientific rigor. PolTREG's dedication to pioneering treatments for autoimmune diseases positions it as an attractive investment opportunity for venture capitalists seeking to support groundbreaking medical advancements.
PolTREG S.A.
Innovative therapies for autoimmune diseases. Global pioneer in cellular therapies based on TREGS cells.
Poland
33 employees
General Information
Get notified when PolTREG S.A. moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track PolTREG S.A.
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
Poland Market
About PolTREG S.A.
Taxonomy: cellular therapies, TREGS cells, autoimmune diseases, type 1 diabetes, multiple sclerosis, clinical trials, genetically modified cells, scientific advisory board, next-generation therapies
No funding data available for PolTREG S.A. yet.
Get notified when PolTREG S.A. raises fundingPolTREG S.A. Alternatives & Competitors
‘Off-the-Shelf’ Curative Cell Therapies
Splash Pharmaceuticals is a privately held clinical stage oncology pharmaceutical company advancing...
Crafting novel therapies to enhance the length and quality of life for seriously ill patients worldw...
FAQ About PolTREG S.A.
Don't just browse. Track.
Signal Tracker monitors PolTREG S.A. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.